A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction (LEPHT)

Gender Preference	None
Age Group	18 - 80 years
Research Start Date	April 1, 2010
Research End Date	May 31, 2017
Principal Investigator	KellyAnn Light-McGroary, MD
Description	The aim of this study is to assess whether increasing oral doses of Riociguat are safe and improve the well-being, symptoms and outcome in patients with pulmonary hypertension associated with left ventricular systolic dysfunction This study is closed to enrollment and is in follow-up phase. Please refer to www.clinicaltrials.gov identifier NCT01065454 for more information.
Contact Info	Cardiomyopathy Treatment Program Page Scovel, RN phone: 319-356-1028 fax: 319-356-7087 email: page-scovel@uiowa.edu
Keywords	span itemProp='description'>cardiac disease ; Cardiomyopathy ; Congestive heart failure ; Heart ; Heart failure ; Left ventricular systolic dysfunction ; Pulmonary hypertension ; Pulmonary hypertension associated with left heart ;

Contact